Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer, Gilead Emails Reveal Behind-The-Scenes Battle Over Malaysia's Drug Pricing, Compulsory Licensing Policies

Executive Summary

Gilead sought the US Trade Representative's intervention to halt sofosbuvir compulsory license, while Pfizer complained about Malaysia regulation requiring disclosure of prices throughout the pharmaceutical supply chain.

You may also be interested in...

Global IP Battle: Drug Pricing, Reimbursement Policies Take Center Stage

USTR's 2018 Special 301 Report moves two countries to Priority Watch List in part because of their pricing policies; AAM says focus should be on government reimbursement rather than extending IP protection.

USTR Takes Aim At Colombia Over Drug Pricing Policy

Colombia has been moved on to the USTR’s 301 Priority Watch List, in part because of a new pricing policy.

Gilead Cornered Into Expanding Access To HIV, Hep C Drugs in Malaysia, Other Countries

Faced with the prospect of a compulsory license in Malaysia, Gilead has reviewed its generic licensing agreements to grant access to low-cost versions of its HIV and hepatitis C drugs in the country and three other middle-income nations.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts